NovaBay Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2004
Net Income	-16.7	-16.27	-6.56	-11.04	-10.49	Upgrade
Depreciation & Amortization	0.2	0.48	0.12	0.05	0.07	Upgrade
Share-Based Compensation	0.29	0.22	0.93	0.53	0.71	Upgrade
Other Operating Activities	5.02	3.25	-4.42	5.73	0.96	Upgrade
Operating Cash Flow	-4.13	-6.65	-9.19	-4.72	-7.93	Upgrade
Capital Expenditures	-0.02	-0.11	-0.05	-0.03	-0.02	Upgrade
Acquisitions	0	0	-11.99	0	0	Upgrade
Investing Cash Flow	-0.02	-0.11	-12.05	-0.03	-0.02	Upgrade
Share Issuance / Repurchase	0.57	1.7	1.78	12.33	6.96	Upgrade
Debt Issued / Paid	1.35	-0.11	0.11	-2.56	2.15	Upgrade
Other Financing Activities	-	3.04	14.91	-	2.6	Upgrade
Financing Cash Flow	1.91	4.63	16.79	9.76	11.7	Upgrade
Net Cash Flow	-2.24	-2.13	-4.45	5.02	3.75	Upgrade
Free Cash Flow	-4.15	-6.77	-9.24	-4.75	-7.95	Upgrade
Free Cash Flow Margin	-28.18%	-46.97%	-90.59%	-47.79%	-120.44%	Upgrade
Free Cash Flow Per Share	-34.46	-147.09	-259.45	-165.79	-449.90	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).